On the other hand, treating patients with PI3K/AKT pathway inhibitors presents a significant challenge due to their associated toxicities, which include stomatitis, rash, hyperglycemia, nausea, diarrhea, and fatigue [7]. Here, AKT1 is linked to Hyperglycemia.